绥美凯治疗效果好吗？

On January 20, 2018, ViiV, a joint venture company under GlaxoSmithKline (hereinafter referred to as GSK), the first complete antiviral treatment regimen drug with dolutegravir (also known as DTG in English) as the core, was officially launched in China. This is also the first complete single-pill compound treatment regimen in the field of HIV treatment in China.

Is Suimeikai treatment effective?

Take a look at the ingredients of the treatment. Suimeikai is composed of three ingredients: DTG (DTG) + Abacavir (ABC) + Lamivudine (3TC). It is a compound treatment agent of integrase inhibitors and nucleoside drugs. Since the advent of the first anti-HIV treatment agent zidovudine (AZT) in 1987, which has brought hope to AIDS patients, more and more drugs have continued to appear, including efavirenz (EVF), Kaletra, tenofovir, and Ascent, until the newly released Tevicay in recent years. Anti-AIDS drugs have experienced the nucleoside With the development of different types of inhibitors, non-nucleoside inhibitors, protease inhibitors and integrase inhibitors in different periods, there are more and more types of drugs, the therapeutic effects are getting better and better, and the side effects are getting less and less. At present, the world has basically entered the era of integrase inhibitor drugs, and the optimization of multi-drug combination programs is constantly innovating. In 2016, GSK launched the integrase DTG (Trivic) in China. This treatment has the advantages of small drug dosage, resistance to drug resistance, and low probability of drug side effects. This time, Trimic uses DTG, an integrase inhibitor, as the core drug, combined with a treatment plan of two backbone drugs, abacavir and lamivudine, and made a single-tablet treatment for promotion, making great progress in the core drug in HAART treatment. In addition, this treatment agent can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and effectively improving the patients' quality of life and work.

Second, look at the experimental results of the treatment. Judging from a large number of clinical trial data, DTG has a low discontinuation rate due to adverse drug reactions (ADR) or virological failure, which are 5.8% and 0.5% respectively. The ADR drops significantly after one year of taking the drug. The most common adverse reactions are gastrointestinal dysfunction, mental disorders and neurological disorders, but the adverse reaction rates are less than 1.5%. From the comparison with patients who failed the first-line regimen of RAL (Ascent) and EVG (Evitegravir), the other two integrase inhibitors, the number of drug-resistant mutations in Trimeq is significantly less than that of the other two drugs, making it less likely to develop drug resistance. In the real world, antiviral treatment-naïve patients treated with DTG have a lower proportion of central nervous system-related (CNS) adverse events than the four drugs RAL (Ascent), DRV/r (darunavir), EFV (efavirenz) and ATV/r (atazanavir). Therefore, the drug safety of Suimeike, which is based on DTG integrase inhibitors, has proven to be controllable. In general, this treatment agent has four main advantages: 1. Excellent efficacy and significant virus suppression effect; 2. The three drugs are equivalent, and both newly-treated and previously treated patients have high drug resistance barriers, which is not easy to lead to drug resistance; 3. It is easy to take and only needs to be taken once a day, without considering food effects; 4. The drug has low side effects and good tolerance, and the discontinuation rate due to drug side effects is low; 5. The metabolic pathway has few interactions with other drugs.

For adults and adolescents, the recommended dose is one tablet once daily. Adults or adolescents whose body weight is less than 40 kg should not be given Trimax because Trimax is a fixed-dose tablet and the dose cannot be reduced. Trimax is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines.